tert-butyl (4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)carbamate | 1258457-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: tert-butyl (4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)carbamate
• 英文别名: tert-butyl N-[[4-[(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)methyl]phenyl]methyl]carbamate
• CAS: 1258457-57-6
• 化学式: C₂₇H₃₃N₅O₂
• 分子量: 459.591
• InChiKey: XRPLRKBJUHZSRY-UHFFFAOYSA-N

物化性质

• 沸点：
  702.4±60.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以62.8 %的产率得到1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine
  参考文献：
  名称：

  [EN] TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES
  [FR] AGONISTES TLR7 ET TLR8 POUR LE TRAITEMENT DU CANCER ET/OU DE MALADIES INFECTIEUSES

  摘要：

  本文揭示了公式（I）或（II）或（III）的化合物：还揭示了通过给予本文所揭示的化合物的治疗有效剂量来刺激免疫反应，引发抗肿瘤免疫反应和治疗患者感染性疾病的方法。还揭示了通过在有效治疗条件下给予本文所揭示的化合物的治疗有效剂量来治疗肿瘤或异常细胞增殖的方法。

  公开号：

  WO2022187809A1
• 作为产物：
  描述：

  tert-butyl (4-(((3-pentanamido-2-chloroquinolin-4-yl)amino)methyl)benzyl)carbamate 在 氨 作用下， 以 甲醇 为溶剂， 生成 tert-butyl (4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)carbamate
  参考文献：
  名称：

  Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7

  摘要：

  Toll-like receptor (TLR)-7 agonists show prominent immunostimulatory activities. The synthesis of a TLR7-active N-1-(4-aminomethyl)benzyl substituted imidazoquinoline 5d served as a convenient precursor for the covalent attachment of fluorophores without significant loss of activity. Fluorescence microscopy experiments show that the fluorescent analogues are internalized and distributed in the endosomal compartment. Flow cytometry experiments using whole human blood show differential partitioning into B, T, and natural killer (NK) lymphocytic subsets, which correlate with the degree of activation in these subsets. These fluorescently-labeled imidazoquinolines will likely be useful in examining the trafficking of TLR7 in immunological synapses. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.093

文献信息

• TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS
  申请人：Torque Therapeutics, Inc.

  公开号：US20210213010A1

  公开（公告）日：2021-07-15

  The present disclosure relates to a method of loading a toll like receptor (TLR)7/8 agonist into a liposome using remote loading and a kit of parts suitable for the loading of a TLR7/8 agonist into a liposome by said method. The present disclosure further relates to a liposome comprising a salt of a TLR7/8 agonist in the liposome interior and to the use of said liposome for stimulation of an immune response and/or treatment of a clinical condition. Finally, the present disclosure relates to a TLR7/8 agonist which is suitable for being remotely loaded into a liposome.
• US8728486B2
  申请人：——

  公开号：US8728486B2

  公开（公告）日：2014-05-20